Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,253.60 | 25.70 | -0.28% |
| CAC 40 | 7,974.85 | 3.07 | 0.04% |
| DAX 40 | 24,385.78 | 7.49 | 0.03% |
| Dow JONES (US) | 46,549.83 | 145.14 | -0.31% |
| FTSE 100 | 9,483.58 | 4.44 | 0.05% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,794.70 | 146.96 | -0.64% |
| Nikkei 225 | 47,950.88 | 6.12 | 0.01% |
| NZX 50 Index | 13,531.29 | 42.05 | 0.31% |
| S&P 500 | 6,711.95 | 28.33 | -0.42% |
| S&P/ASX 200 | 8,956.80 | 19.10 | -0.21% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |